IPP Bureau
Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories India for Rs. 16 Cr
By IPP Bureau - June 23, 2025
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Emcure to acquire remaining stake in Zuventus Healthcare
By IPP Bureau - June 23, 2025
The transaction is expected to close in Q2 FY 2026
Unichem receives Form 483 from USFDA with 3 observations for Roha API facility
By IPP Bureau - June 23, 2025
The company will provide the necessary response to USFDA within stipulated 15 days
BASF opens new GMP Solution Center in US
By IPP Bureau - June 23, 2025
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
By IPP Bureau - June 21, 2025
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study
By IPP Bureau - June 21, 2025
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
By IPP Bureau - June 21, 2025
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia
By IPP Bureau - June 21, 2025
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Healthcare Triangle launches Malaysian subsidiary QuantumNexis
By IPP Bureau - June 20, 2025
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
USFDA concludes inspection of NATCO’s Pharma Division, Kothur
By IPP Bureau - June 20, 2025
The company received seven observations in the Form-483
Sanner commences manufacturing critical injection-molded components in USA
By IPP Bureau - June 20, 2025
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
UFlex introduces FSSAI compliant single-pellet solution for food packaging
By IPP Bureau - June 20, 2025
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Briefs: Hikal and Sun Pharma
By IPP Bureau - June 17, 2025
Sun Pharma gets 8 observations from USFDA for Halol facility
Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
By IPP Bureau - June 17, 2025
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
